FOXA2 and fatty liver disease: Furthermore, oe-Foxa2-induced FAS and ACC downregulation and CPT1α upregulation was reversed by LPS (NF-κB/IKK pathway activator) treatment, which indicates that Foxa2 attenuates hepatic steatosis may relate to the inhibition of NF-κB/IKK pathway.